{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:50:48Z","timestamp":1791021048331,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The relationship between the circulating antioxidant uric acid (UA) and Parkinson\u2019s disease (PD) has attracted much interest. This review of the evidence indicating whether UA may have a protective role in the development and\/or progression of PD draws on the findings of reduced serum UA in PD, critically assesses the more equivocal genetic results, and discusses experimental observations that UA may provide protection against the pathogenic mechanisms of PD.<\/jats:p>","DOI":"10.1038\/s41531-025-01169-8","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:01:28Z","timestamp":1763557288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A review of the evidence for a protective role of uric acid in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Hanxiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/rheumatology\/keq204","volume":"49","author":"B \u00c1lvarez-Lario","year":"2010","unstructured":"\u00c1lvarez-Lario, B. & Macarr\u00f3n-Vicente, J. Uric acid and evolution. Rheumatology 49, 2010\u20132015 (2010).","journal-title":"Rheumatology"},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2015.11.026","volume":"29","author":"M Kanbay","year":"2016","unstructured":"Kanbay, M. et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur. J. Intern. Med. 29, 3\u20138 (2016).","journal-title":"Eur. J. Intern. Med."},{"key":"1169_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.semarthrit.2020.04.007","volume":"50","author":"RT Keenan","year":"2020","unstructured":"Keenan, R. T. The biology of urate. Semin. Arthritis Rheum. 50, S2\u2013S10 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1169_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/ng.2500","volume":"45","author":"A K\u00f6ttgen","year":"2013","unstructured":"K\u00f6ttgen, A. et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat. Genet. 45, 145\u2013154 (2013).","journal-title":"Nat. Genet."},{"key":"1169_CR5","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41588-019-0504-x","volume":"51","author":"A Tin","year":"2019","unstructured":"Tin, A. et al. Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nat. Genet. 51, 1459\u20131474 (2019).","journal-title":"Nat. Genet."},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1042\/bj2350747","volume":"235","author":"KJ Davies","year":"1986","unstructured":"Davies, K. J., Sevanian, A., Muakkassah-Kelly, S. F. & Hochstein, P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem. J. 235, 747\u2013754 (1986).","journal-title":"Biochem. J."},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.26467","volume":"92","author":"MT Peri\u00f1\u00e1n","year":"2022","unstructured":"Peri\u00f1\u00e1n, M. T. et al. Effect modification between genes and environment and Parkinson\u2019s disease risk. Ann. Neurol. 92, 715\u2013724 (2022).","journal-title":"Ann. Neurol."},{"key":"1169_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/neup.12812","volume":"42","author":"CJ Choong","year":"2022","unstructured":"Choong, C. J. & Mochizuki, H. Neuropathology of \u03b1-synuclein in Parkinson\u2019s disease. Neuropathology 42, 93\u2013103 (2022).","journal-title":"Neuropathology"},{"key":"1169_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong, Y. C. & Krainc, D. \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Med. 23, 1\u201313 (2017).","journal-title":"Nat. Med."},{"key":"1169_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0361-9230(94)90285-2","volume":"33","author":"WH Church","year":"1994","unstructured":"Church, W. H. & Ward, V. L. Uric acid is reduced in the substantia nigra in Parkinson\u2019s disease: effect on dopamine oxidation. Brain Res. Bull. 33, 419\u2013425 (1994).","journal-title":"Brain Res. Bull."},{"key":"1169_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","volume":"52","author":"P Riederer","year":"1989","unstructured":"Riederer, P. et al. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J. Neurochem. 52, 515\u2013520 (1989).","journal-title":"J. Neurochem."},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"e38947","DOI":"10.1097\/MD.0000000000038947","volume":"103","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Association between high uric acid and the risk of Parkinson\u2019s disease: a meta-analysis. Medecine 103, e38947 (2024).","journal-title":"Medecine"},{"key":"1169_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00702-019-02119-4","volume":"127","author":"H Liu","year":"2020","unstructured":"Liu, H., Wei, X., Yang, W. & Reynolds, G. P. Agricultural work and reduced circulating uric acid are both associated with initial hospital admission for Parkinson\u2019s disease. J. Neural Transm. 127, 779\u2013783 (2020).","journal-title":"J. Neural Transm."},{"key":"1169_CR14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","volume":"65","author":"MA Schwarzschild","year":"2008","unstructured":"Schwarzschild, M. A. et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65, 716\u2013723 (2008).","journal-title":"Arch. Neurol."},{"key":"1169_CR15","first-page":"245","volume":"58","author":"A D\u0103n\u0103u","year":"2022","unstructured":"D\u0103n\u0103u, A., Dumitrescu, L., Lefter, A. & Popescu, B. O. Serum uric acid levels in parkinson\u2019s disease: a cross-sectional electronic medical record database study from a tertiary referral centre in Romania. Medecine 58, 245 (2022).","journal-title":"Medecine"},{"key":"1169_CR16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/art.24193","volume":"59","author":"M De Vera","year":"2008","unstructured":"De Vera, M. et al. Gout and the risk of Parkinson\u2019s disease: a cohort study. Arthritis Rheum. 59, 1549\u20131554 (2008).","journal-title":"Arthritis Rheum."},{"key":"1169_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105402","volume":"89","author":"MA Pou","year":"2022","unstructured":"Pou, M. A. et al. Risk of Parkinson\u2019s disease in a gout Mediterranean population: a case-control study. Jt. Bone Spine 89, 105402 (2022).","journal-title":"Jt. Bone Spine"},{"key":"1169_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02874-0","volume":"22","author":"A Fazlollahi","year":"2022","unstructured":"Fazlollahi, A. et al. Association between gout and the development of Parkinson\u2019s disease: a systematic review and meta-analysis. BMC Neurol. 22, 383 (2022).","journal-title":"BMC Neurol."},{"key":"1169_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41531-022-00433-5","volume":"8","author":"H Chang","year":"2022","unstructured":"Chang, H., Wang, B., Shi, Y. & Zhu, R. Dose-response meta-analysis on urate, gout, and the risk for Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 160 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1169_CR20","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s10067-020-05090-8","volume":"39","author":"M Wu","year":"2020","unstructured":"Wu, M., Tian, Y., Wang, Q. & Guo, C. Gout: a disease involved with complicated immunoinflammatory responses: a narrative review. Clin. Rheumatol. 39, 2849\u20132859 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1169_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3233\/JAD-2010-1330","volume":"19","author":"GL Bowman","year":"2010","unstructured":"Bowman, G. L., Shannon, J., Frei, B., Kaye, J. A. & Quinn, J. F. Uric acid as a CNS antioxidant. J. Alzheimer\u2019s Dis. 19, 1331\u20131336 (2010).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"1169_CR22","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","volume":"66","author":"A Ascherio","year":"2009","unstructured":"Ascherio, A. et al. Urate as a predictor of the rate of clinical decline in Parkinson's disease. Arch. Neurol. 66, 1460\u20131468 (2009).","journal-title":"Arch. Neurol."},{"key":"1169_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41531-023-00505-0","volume":"9","author":"L Has\u00edkov\u00e1","year":"2023","unstructured":"Has\u00edkov\u00e1, L. et al. Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 60 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1169_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-020-01147-2","volume":"21","author":"T Lukkunaprasit","year":"2020","unstructured":"Lukkunaprasit, T. et al. The association between genetic polymorphisms in ABCG2 and SLC2A9 and urate: an updated systematic review and meta-analysis. BMC Med. Genet. 21, 210 (2020).","journal-title":"BMC Med. Genet."},{"key":"1169_CR25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1002\/mds.25507","volume":"28","author":"I Gonz\u00e1lez-Aramburu","year":"2013","unstructured":"Gonz\u00e1lez-Aramburu, I. et al. Genetic variability related to serum uric acid concentration and risk of Parkinson\u2019s disease. Mov. Disord. 28, 1737\u20131740 (2013).","journal-title":"Mov. Disord."},{"key":"1169_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.parkreldis.2018.04.031","volume":"53","author":"KC Hughes","year":"2018","unstructured":"Hughes, K. C. et al. Genetic variants related to urate and risk of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 53, 4\u20139 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ana.24281","volume":"76","author":"KC Simon","year":"2014","unstructured":"Simon, K. C. et al. Mendelian randomization of serum urate and parkinson disease progression. Ann. Neurol. 76, 862\u2013868 (2014).","journal-title":"Ann. Neurol."},{"key":"1169_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ana.25292","volume":"84","author":"CJ Kobylecki","year":"2018","unstructured":"Kobylecki, C. J., Nordestgaard, B. G. & Afzal, S. Plasma urate and risk of Parkinson\u2019s disease: a mendelian randomization study. Ann. Neurol. 84, 178\u2013190 (2018).","journal-title":"Ann. Neurol."},{"key":"1169_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-024-01476-x","volume":"16","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Serum urate levels and neurodegenerative outcomes: a prospective cohort study and mendelian randomization analysis of the UK Biobank. Alzheimers Res. Ther. 16, 106 (2024).","journal-title":"Alzheimers Res. Ther."},{"key":"1169_CR30","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/mds.28662","volume":"36","author":"R Coneys","year":"2021","unstructured":"Coneys, R., Storm, C. S., Kia, D. A., Almramhi, M. & Wood, N. W. Mendelian randomisation finds no causal association between urate and Parkinson\u2019s disease progression. Mov. Disord. 36, 2182\u20132187 (2021).","journal-title":"Mov. Disord."},{"key":"1169_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2018.08.005","volume":"53","author":"EG Brown","year":"2018","unstructured":"Brown, E. G., Goldman, S. M. & Tanner, C. M. Mendel and urate: acid test or random noise?. Parkinsonism Relat. Disord. 53, 1\u20133 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1169_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27198-4","volume":"12","author":"A Tin","year":"2021","unstructured":"Tin, A. et al. Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus. Nat. Commun. 12, 7173 (2021).","journal-title":"Nat. Commun."},{"key":"1169_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1073\/pnas.1217296110","volume":"110","author":"X Chen","year":"2013","unstructured":"Chen, X. et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. USA 110, 300\u2013305 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1169_CR34","doi-asserted-by":"publisher","first-page":"e0264696","DOI":"10.1371\/journal.pone.0264696","volume":"17","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Uricase-deficient rats with similarly stable serum uric acid to human\u2019s are sensitive model animals for studying hyperuricemia. PLoS ONE 17, e0264696 (2022).","journal-title":"PLoS ONE"},{"key":"1169_CR35","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.bbrc.2017.10.004","volume":"493","author":"TT Huang","year":"2017","unstructured":"Huang, T. T., Hao, D. L., Wu, B. N., Mao, L. L. & Zhang, J. Uric acid demonstrates neuroprotective effect on Parkinson\u2019s disease mice through Nrf2-ARE signaling pathway. Biochem. Biophys. Res. Commun. 493, 1443\u20131449 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1169_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1175-8","volume":"15","author":"LH Bao","year":"2018","unstructured":"Bao, L. H. et al. Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson\u2019s disease. J. Neuroinflam. 15, 131 (2018).","journal-title":"J. Neuroinflam."},{"key":"1169_CR37","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1471-4159.2009.06040.x","volume":"109","author":"S Guerreiro","year":"2009","unstructured":"Guerreiro, S. et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J. Neurochem. 109, 1118\u20131128 (2009).","journal-title":"J. Neurochem."},{"key":"1169_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fnmol.2018.00021","volume":"11","author":"M Bi","year":"2018","unstructured":"Bi, M., Jiao, Q., Du, X. & Jiang, H. Glut9-mediated urate uptake is responsible for its protective effects on dopaminergic neurons in Parkinson\u2019s disease models. Front. Mol. Neurosci. 11, 21 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"1169_CR39","doi-asserted-by":"publisher","first-page":"e100286","DOI":"10.1371\/journal.pone.0100286","volume":"9","author":"N Zhang","year":"2014","unstructured":"Zhang, N. et al. Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS ONE 9, e100286 (2014).","journal-title":"PLoS ONE"},{"key":"1169_CR40","doi-asserted-by":"publisher","first-page":"1117491","DOI":"10.3389\/fnagi.2023.1117491","volume":"15","author":"YJ Shin","year":"2023","unstructured":"Shin, Y. J. et al. Uric acid regulates \u03b1-synuclein transmission in Parkinsonian models. Front. Aging Neurosci. 15, 1117491 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"1169_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.expneurol.2017.08.007","volume":"297","author":"YL Sheng","year":"2017","unstructured":"Sheng, Y. L. et al. Urate promotes SNCA\/\u03b1-synuclein clearance via regulating mTOR-dependent macroautophagy. Exp. Neurol. 297, 138\u2013147 (2017).","journal-title":"Exp. Neurol."},{"key":"1169_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neulet.2017.09.001","volume":"659","author":"N Uemura","year":"2017","unstructured":"Uemura, N. et al. Immunoreactivity of urate transporters, GLUT9 and URAT1, is located in epithelial cells of the choroid plexus of human brains. Neurosci. Lett. 659, 99\u2013103 (2017).","journal-title":"Neurosci. Lett."},{"key":"1169_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12987-016-0046-x","volume":"13","author":"NH Tomioka","year":"2016","unstructured":"Tomioka, N. H. et al. Immunohistochemical and in situ hybridization study of urate transporters GLUT9\/URATv1, ABCG2, and URAT1 in the murine brain. Fluids Barriers CNS 13, 22 (2016).","journal-title":"Fluids Barriers CNS"},{"key":"1169_CR44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1528-1167.2005.66604.x","volume":"46","author":"E Aronica","year":"2005","unstructured":"Aronica, E. et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46, 849\u2013857 (2005).","journal-title":"Epilepsia"},{"key":"1169_CR45","doi-asserted-by":"publisher","first-page":"7230","DOI":"10.3390\/ijms21197230","volume":"21","author":"Y Chiba","year":"2020","unstructured":"Chiba, Y. et al. Glucose, fructose, and urate transporters in the choroid plexus epithelium. Int. J. Mol. Sci. 21, 7230 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1169_CR46","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.brainres.2016.12.022","volume":"1657","author":"SA Oppelt","year":"2017","unstructured":"Oppelt, S. A., Zhang, W. & Tolan, D. R. Specific regions of the brain are capable of fructose metabolism. Brain Res. 1657, 312\u2013322 (2017).","journal-title":"Brain Res."},{"key":"1169_CR47","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1046\/j.1528-1157.2003.21803.x","volume":"44","author":"SM Sisodiya","year":"2003","unstructured":"Sisodiya, S. M. et al. Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 44, 1388\u20131396 (2003).","journal-title":"Epilepsia"},{"key":"1169_CR48","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnen\/nlz142","volume":"79","author":"EA van Vliet","year":"2020","unstructured":"van Vliet, E. A. et al. Expression and cellular distribution of p-glycoprotein and breast cancer resistance protein in amyotrophic lateral sclerosis patients. J. Neuropathol. Exp. Neurol. 79, 266\u2013276 (2020).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1169_CR49","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/epi.14505","volume":"59","author":"LD Weidner","year":"2018","unstructured":"Weidner, L. D. et al. The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue. Epilepsia 59, 1507\u20131517 (2018).","journal-title":"Epilepsia"},{"key":"1169_CR50","doi-asserted-by":"publisher","first-page":"789","DOI":"10.4049\/jimmunol.2000319","volume":"205","author":"Q Ma","year":"2020","unstructured":"Ma, Q. et al. Soluble uric acid is an intrinsic negative regulator of monocyte activation in monosodium urate crystal-induced tissue inflammation. J. Immunol. 205, 789\u2013800 (2020).","journal-title":"J. Immunol."},{"key":"1169_CR51","doi-asserted-by":"publisher","first-page":"1282890","DOI":"10.3389\/fimmu.2023.1282890","volume":"14","author":"D Li","year":"2023","unstructured":"Li, D. et al. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. Front. Immunol. 14, 1282890 (2023).","journal-title":"Front. Immunol."},{"key":"1169_CR52","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nbd.2015.08.022","volume":"82","author":"R Bakshi","year":"2015","unstructured":"Bakshi, R. et al. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiol. Dis. 82, 574\u2013579 (2015).","journal-title":"Neurobiol. Dis."},{"key":"1169_CR53","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1471-4159.2012.07820.x","volume":"123","author":"S Cipriani","year":"2012","unstructured":"Cipriani, S. et al. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J. Neurochem. 123, 172\u2013181 (2012).","journal-title":"J. Neurochem."},{"key":"1169_CR54","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1161\/STROKEAHA.116.014672","volume":"47","author":"S Amaro","year":"2016","unstructured":"Amaro, S. et al. Uric acid therapy prevents early ischemic stroke progression: a Tertiary analysis of the URICO-ICTUS trial (Efficacy study of combined treatment with uric acid and r-tPA in acute ischemic stroke). Stroke 47, 2874\u20132876 (2016).","journal-title":"Stroke"},{"key":"1169_CR55","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2021.10207","volume":"326","author":"MA Schwarzschild","year":"2021","unstructured":"Schwarzschild, M. A. et al. Effect of urate-elevating inosine on early parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA 326, 926\u2013939 (2021).","journal-title":"JAMA"},{"key":"1169_CR56","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/jnnp-2015-311890","volume":"87","author":"AJ Noyce","year":"2016","unstructured":"Noyce, A. J., Lees, A. J. & Schrag, A. E. The prediagnostic phase of Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 87, 871\u2013878 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1169_CR57","first-page":"912","volume":"48","author":"V Gallo","year":"2019","unstructured":"Gallo, V. et al. Exploring causality of the association between smoking and Parkinson\u2019s disease. Int. J. Epidemiol. 48, 912\u2013925 (2019).","journal-title":"Int. J. Epidemiol."},{"key":"1169_CR58","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.parkreldis.2006.11.004","volume":"13","author":"B Kandinov","year":"2007","unstructured":"Kandinov, B., Giladi, N. & Korczyn, A. D. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 13, 243\u2013245 (2007).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1169_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JPD-191860","volume":"10","author":"C Koros","year":"2020","unstructured":"Koros, C. et al. Serum uric acid level as a biomarker in idiopathic and genetic (p.A53T Alpha-Synuclein Carriers) Parkinson\u2019s disease: data from the PPMI study. J. Parkinsons Dis. 10, 481\u2013487 (2020).","journal-title":"J. Parkinsons Dis."},{"key":"1169_CR60","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ana.24504","volume":"78","author":"A Nazeri","year":"2015","unstructured":"Nazeri, A. et al. Genome-wide variant by serum urate interaction in Parkinson\u2019s disease. Ann. Neurol. 78, 731\u2013741 (2015).","journal-title":"Ann. Neurol."},{"key":"1169_CR61","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mds.30067","volume":"40","author":"K Atterling Brolin","year":"2025","unstructured":"Atterling Brolin, K. et al. Environmental risk factors for Parkinson\u2019s disease: a critical review and policy implications. Mov. Disord. 40, 204\u2013221 (2025).","journal-title":"Mov. Disord."},{"key":"1169_CR62","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/molbev\/msw116","volume":"33","author":"PK Tan","year":"2016","unstructured":"Tan, P. K., Farrar, J. E., Gaucher, E. A. & Miner, J. N. Coevolution of URAT1 and uricase during primate evolution: implications for serum urate homeostasis and gout. Mol. Biol. Evol. 33, 2193\u20132200 (2016).","journal-title":"Mol. Biol. Evol."},{"key":"1169_CR63","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s43856-025-01044-w","volume":"5","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. Sex-specific DNA methylation associations with circulating urate levels and BCG-induced urate changes. Commun. Med. 5, 321 (2025).","journal-title":"Commun. Med."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01169-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:03:02Z","timestamp":1763560982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01169-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01169-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}